1-774-INCLINE

Humans have spent centuries wanting to form novel therapies to extend and increase the well-being or our lives for this and future generations. With the advancement in molecular and cellular biology, the ability of true healing is being discovered in our own cells. Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stemshot provides products and distinguishes themselves in the Stemcell industry with a higher concentration in therapeutic elements and less distracted processing.  Our protocols are less destructive, and leave in tact the target cells that are destroyed under competitors processing methods.

 

Human Cell and Tissue Products

Research has shown that the utilization of human cell and tissue products from the umbilical cord and alternative birth tissues may have a massive affect on the major injuries and human physical ailments. We have seen a six fold increase in engraftment due to the combination of the various compartments.  Bone marrow-derived mesenchymal stem cells (MSCs) have been found to promote engraftment after hematopoietic stem cell transplantation. However, harvesting MSCs from bone marrow involves an invasive procedure. Then again, MSCs can be easily obtained from umbilical cords without harm to the donors. Cord tissue mesenchymal stem cells have a shorter doubling time than adult mesenchymal stem cells and also have more potential divisions. They also secrete and contain a more potent and regenerative profile of growth factors. The fitness of adult mesenchymal stem cells, as well as the growth factors they secrete, declines with age. Medical research has shown that birth tissue has greater fitness than MSC derived allograft will have greater fitness than adult mesenchymal stem cells due to the higher concentration of growth factors and the younger and more fit cells.  Due to the screening process and probability, the allograft is less likely to contain any genetic or epigenetic defects present in the patient’s tissues.

 

Proprietary Processing

StemShot® utilizes advanced tissue gathering techniques to make the most effective manipulated allograft tissue product.

StemShot® and StemVive™products are developed and produced by Utah Cord Bank (UCB).   StemShot® and StemVive™ are the first products to include minimally manipulated material from membrane, cord tissue and cord blood. We call this the Triple Threat.  Our tissue donor program performs in depth background checks and testing so as to ensure the quality of the donation.  Over the last year, we have seen 100% growth in clinical practices have already found a reputable supply of stem cell therapy products. We lead the industry with our proprietary processing and supplying clinicians with a quality product.

 

Quality and Experience

UCB’s tissue labs are focused on creating products for use by orthopedic, sports medicine, wound care and pain management practitioners to aid in their patients’ regenerative health needs. The StemShot® and StemVive team includes expert scientists and technicians with decades of experience with the with human tissue products.  UCB provides products and distinguishes themselves in the stem cell industry with a higher concentration in therapeutic elements and less distracted processing.  Our protocols are less destructive and leave in tact the target cells that are destroyed under competitors processing methods.  StemShot® and StemVive™ products are developed and produced by Utah Cord Bank (UCB).

 

StemShot uses a patent pending process to produce its minimally manipulated product which conforms to the regulations
and the FDA’s definition found in HTC/P 361 products in accordance with FDA Article 21 CFR Part 1271.
Following these standards allows StemShot to sell approved allograft products with confidence to Healthcare Providers.